Asset Acquisition, Contingent Consideration, Liability

No definition available.

Name:	amag_AssetAcquisitionContingentConsiderationLiability
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Asset Acquisition, Contingent Consideration Terms, Net Sales Threshold For Commercial Product Life

+ References

No definition available.

+ Details

Name:	amag_AssetAcquisitionContingentConsiderationTermsNetSalesThresholdForCommercialProductLife
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Asset Acquisition, Contingent Consideration Terms, Royalty Percentage

+ References

No definition available.

+ Details

Name:	amag_AssetAcquisitionContingentConsiderationTermsRoyaltyPercentage
Namespace Prefix:	amag_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Asset Acquisition, Contingent Consideration Terms, Threshold Period After Initial Sale

+ References

No definition available.

+ Details

Name:	amag_AssetAcquisitionContingentConsiderationTermsThresholdPeriodAfterInitialSale
Namespace Prefix:	amag_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Asset Acquisition, Potential Milestone Payment, Triggering Event, Threshold Amount

+ References

No definition available.

+ Details

Name:	amag_AssetAcquisitionPotentialMilestonePaymentTriggeringEventThresholdAmount
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Option Agreement, Contingent Consideration, Liability

+ References

No definition available.

+ Details

Name:	amag_OptionAgreementContingentConsiderationLiability
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Option Agreement, Potential Sales Milestone Payment, Triggering Event, Threshold Amount

+ References

No definition available.

+ Details

Name:	amag_OptionAgreementPotentialSalesMilestonePaymentTriggeringEventThresholdAmount
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Payments Related to Collaborative Arrangement

+ References

No definition available.

+ Details

Name:	amag_PaymentsRelatedToCollaborativeArrangement
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585

+ Details

Name:	us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(17))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(19))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(25))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=amag_VeloBioLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_RegulatoryMilestoneAchievementU.S.FoodAndDrugAdministrationApprovalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_AnnualSalesMilestoneAchievementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_RegulatoryMilestoneAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_CommercialMilestonePaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=amag_EndoceuticsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=amag_IntrarosaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_FirstSalesMilestoneAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_SecondSalesMilestoneAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_ThirdSalesMilestoneAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_TieredRoyaltiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=amag_PalatinTechnologiesInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=amag_BremelanotideProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_RegulatoryAndCommercialMilestonePaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_RegulatoryMilestoneAchievementAcceptanceByU.S.FoodAndDrugAdministrationOfNewDrugApplicationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=amag_LumaraHealthInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_FirstMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies (Details) - USD ($) $ in Thousands		1 Months Ended		3 Months Ended			9 Months Ended
	Apr. 03, 2017	Sep. 30, 2018	Feb. 28, 2017	Sep. 30, 2018	Jun. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Nov. 30, 2014
Commitments
Minimum purchase commitments		$ 66,400		$ 66,400			$ 66,400
Contingent consideration paid							87	$ 165
Acquired in-process research and development				12,500		$ 0	32,500	65,845
Contingent consideration accrued for the acquisition of the Intrarosa intangible asset		0		0		$ 9,300	0	$ 9,300
Velo Bio, LLC [Member] \| Regulatory Milestone Achievement, U.S.Food And Drug Administration Approval
Commitments
Option agreement, milestone payments		30,000		30,000			30,000
Velo Bio, LLC [Member] \| Annual Sales Milestone Achievements
Commitments
Option agreement, milestone payments		240,000		240,000			240,000
Velo Bio, LLC [Member] \| Regulatory Milestone Achievement
Commitments
Option agreement, milestone payments		5,000		5,000			5,000
Velo Bio, LLC [Member] \| Commercial Milestone Payments
Commitments
Option agreement, milestone payments		10,000		10,000			10,000
Endoceutics, Inc.
Commitments
Payments related to collaborative arrangement	$ 50,000
Endoceutics, Inc. \| Intrarosa \| First Sales Milestone Achievement
Commitments
Contingent consideration accrued for the acquisition of the Intrarosa intangible asset	15,000	15,000		15,000			15,000
Potential milestone payment, triggering event, sales	150,000						150,000
Endoceutics, Inc. \| Intrarosa \| Second Sales Milestone Achievement
Commitments
Contingent consideration accrued for the acquisition of the Intrarosa intangible asset	30,000	30,000		30,000			30,000
Potential milestone payment, triggering event, sales	300,000						300,000
Endoceutics, Inc. \| Intrarosa \| Third Sales Milestone Achievement
Commitments
Contingent consideration accrued for the acquisition of the Intrarosa intangible asset	850,000	850,000		850,000			850,000
Potential milestone payment, triggering event, sales	500,000						500,000
Endoceutics, Inc. \| Intrarosa \| Tiered Royalties
Commitments
Potential milestone payment, triggering event, sales	$ 150,000						$ 150,000
Royalty percentage, maximum	20.00%						20.00%
Net sales threshold, future contingent payments	$ 1,000,000						$ 1,000,000
Period after first commercial sale	10 years						10 years
Palatin Technologies, Inc.
Commitments
Payments related to collaborative arrangement			$ 60,000
Palatin Technologies, Inc. \| Bremelanotide Products \| Regulatory Milestone Achievement, U.S.Food And Drug Administration Approval
Commitments
Contingent consideration accrued for the acquisition of the Intrarosa intangible asset		60,000		60,000			$ 60,000
Palatin Technologies, Inc. \| Bremelanotide Products \| Regulatory And Commercial Milestone Payments
Commitments
Contingent consideration accrued for the acquisition of the Intrarosa intangible asset		380,000		380,000			380,000
Palatin Technologies, Inc. \| Bremelanotide Products \| Regulatory Milestone Achievement, Acceptance By U.S.Food And Drug Administration Of New Drug Application
Commitments
Payments related to collaborative arrangement					$ 20,000
Minimum \| Velo Bio, LLC [Member] \| Annual Sales Milestone Achievements
Commitments
Option agreement annual net sales thresholds		300,000
Maximum \| Velo Bio, LLC [Member] \| Annual Sales Milestone Achievements
Commitments
Option agreement annual net sales thresholds		900,000
Lumara Health Inc.
Commitments
Contingent consideration (up to)									$ 350,000
Business acquisition, contingent consideration, liability		$ 50,000		$ 50,000			50,000
Lumara Health Inc. \| Annual Net Sales Milestone
Commitments
Contingent consideration paid							$ 150,000